Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Supervisors info:
Ζαγουρή Φλώρα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπουσα
Καστρίτης Ευστάθιος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Γαβριατοπούλου Μαρία, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Ανοσοθεραπεία στον HER-2 θετικό καρκίνο του μαστού: Συστηματική ανασκόπηση
Translated title:
Immunotherapy in HER-2 positive Breast Cancer: Systematic Review
Summary:
Breast cancer is the most common cancer in women. Her-2 positive Breast Cancer is an aggressive subtype and despite the fact that HER2-targeted treatment has improved the overall survival of patients with HER2-postive metastatic breast cancer with median OS exceeding 5 years, there is a need for even better treatments. The most promising Immunotherapeutic agents are targeting PD-1/PD-L1 and CTLA-4 pathways and are critical to the immune system’s ability to control cancer growth. These pathways are often called immune checkpoints. Many cancers use these pathways to escape the immune system. Specific immunotherapeutic antibodies are blocking these pathways and are called immune checkpoint inhibitors. Once the immune system is able to find and respond to the cancer, it can stop or slow cancer growth. This is a systematic review in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. It synthesizes all available data emerging from clinical trials and evaluates the efficacy and safety of checkpoint inhibitors in Metastatic, Adjuvant and Neoadjuvant setting of HER-2 positive Breast Cancer. These agents are used alone or in combination with chemotherapy or other drugs. Despite the fact that checkpoint inhibitors are proven active in HER-2 Breast Cancer it is not clear from Phase II /III trials that they are a breakthrough therapy. The immune related toxicities are quite different from those of the chemotherapeutic agents and their management is a new challenge in oncology. In any case many ongoing randomized clinical trials are comparing immunotherapeutic agents with standard treatments in quest of defining the exact role of these agents and the biomarker analysis may further optimize patient selection.
Main subject category:
Health Sciences
Keywords:
Breast cancer; Checkpoint inhibitor; Immunotherapy; HER2-positive breast cancer
File:
File access is restricted only to the intranet of UoA.
Gkoumas Georgios Master.pdf
1 MB
File access is restricted only to the intranet of UoA.
